Template:Available forms of progesterone
Revision as of 14:40, 2 October 2020 by imported>Medgirl131 (Further compact + improve appearance.)
| Route/form | Dose | Brand name | Availability[lower-alpha 2] |
|---|---|---|---|
| Oral capsule | 100, 200, 300 mg | Prometrium[lower-alpha 3] | Widespread |
| Oral tablet (SR) | 200, 300, 400 mg | Dubagest SR[lower-alpha 3] | India |
| Sublingual tablet | 10, 25, 50, 100 mg | Luteina[lower-alpha 3] | Europe[lower-alpha 4] |
| Transdermal gel[lower-alpha 5] | 1% (25 mg) | Progestogel | Europe |
| Vaginal capsule | 100, 200 mg | Utrogestan | Widespread |
| Vaginal tablet | 100 mg | Endometrin[lower-alpha 3] | Widespread |
| Vaginal gel | 4, 8% (45, 90 mg) | Crinone[lower-alpha 3] | Widespread |
| Vaginal suppository | 200, 400 mg | Cyclogest | Europe |
| Vaginal ring | 10 mg/day[lower-alpha 6] | Fertiring[lower-alpha 3] | South America[lower-alpha 7] |
| Rectal suppository | 200, 400 mg | Cyclogest | Europe |
| Intrauterine device | 38 mg | Progestasert | Discontinued |
| IM (oil solution) | 2, 5, 10, 20, 25, 50, 100 mg/mL |
Proluton[lower-alpha 3] | Widespread |
| IM (aq. susp.) | 12.5, 30, 100 mg/mL | Agolutin[lower-alpha 3] | Europe[lower-alpha 8] |
| IM (emulsion) | 5, 10, 25 mg/mL | Di-Pro-Emulsion | Discontinued |
| IM (microsphere) | 20, 100 mg/mL | ProSphere[lower-alpha 3] | Mexico |
| SC (aq. solution) | 25 mg/vial | Prolutex | Europe |
| SC implant | 50, 100 mg | Proluton[lower-alpha 3] | Discontinued |
| IV (aq. solution) | 20 mg/mL | Primolut | Discontinued |
Sources and footnotes:
| |||
See also
- Progesterone (medication) § Available forms
- Pharmacokinetics of progesterone § Routes of administration
- Template:Available forms of estradiol
- Template:Available forms of testosterone
References
- ↑ "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 26 July 2018.
- ↑ Engel J, Kleemann A, Kutscher B, Reichert D (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. pp. 1145–. ISBN 978-3-13-179275-4.
- ↑ Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 2168–. ISBN 978-0-7817-1750-2.
- ↑ Anita MV, Jain S, Goel N (31 July 2018). Use of Progestogens in Clinical Practice of Obstetrics and Gynecology. JP Medical Ltd. pp. 4–. ISBN 978-93-5270-218-3.
- ↑ Sauer MV (1 March 2013). Principles of Oocyte and Embryo Donation. Springer Science & Business Media. pp. 7, 117–118. ISBN 978-1-4471-2392-7.
- ↑ Elder K, Dale B (2 December 2010). In-Vitro Fertilization. Cambridge University Press. pp. 26–. ISBN 978-1-139-49285-0.
- ↑ https://web.archive.org/web/20191230051017/https://mx.prvademecum.com/medicamento/prosphere-11003/
- ↑ Heinrich Kahr (8 March 2013). Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. Springer-Verlag. pp. 21–. ISBN 978-3-7091-5694-0.
- ↑ Basic Sex Hormone Therapy. Schering A.G. 1962. p. 96.
- ↑ Current Medicine and Drugs. 1962. p. 40.
Primolut Intravenous (Schering A.G. Berlin)
- ↑ Haleem S, Khan MI (March 2015). "Changing Indian Market Trends of NMP: A Review" (PDF). International Journal of Pharma Research & Review. 4 (3): 28–30. ISSN 2278-6074.
| Editors can experiment in this template's sandbox (create | mirror) and testcases (create) pages. Subpages of this template. |